Combined tests show promise for pulmonary embolism screening
This article was originally published in Clinica
Pulmonary embolism can be ruled out more rapidly, more cheaply and at less risk to the patient, by using a combination of two minimally invasive bedside tests, rather than pulmonary vascular imaging. That is the finding of a multicentre US study.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.